Compare CRSR & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSR | CMPX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 693.8M | 752.4M |
| IPO Year | 2020 | N/A |
| Metric | CRSR | CMPX |
|---|---|---|
| Price | $6.18 | $5.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $9.75 | ★ $13.44 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 02-11-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,449,248,000.00 | N/A |
| Revenue This Year | $12.96 | N/A |
| Revenue Next Year | $9.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.79 | N/A |
| 52 Week Low | $5.35 | $1.33 |
| 52 Week High | $13.02 | $5.86 |
| Indicator | CRSR | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 53.18 |
| Support Level | $6.08 | $4.83 |
| Resistance Level | $6.33 | $5.27 |
| Average True Range (ATR) | 0.23 | 0.28 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 15.08 | 33.51 |
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.